Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity CancerInterventions:   Drug: WEE1 inhibitor MK-1775;   Drug: gemcitabine hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacological studySponsor:   National Cancer Institute (NCI)Recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials